nab1-paclitaxel (Abraxane) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC): An International, Open-label, Multi-centre, Phase 2 Study (LAPACT).
This clinical study is in subjects who are 18 years old or older with locally advanced
pancreatic cancer who have not received prior treatment for their pancreatic cancer. The
study treats all subjects with nab-Paclitaxel plus gemcitabine for approximately 6 months of
treatment. Subjects who complete the treatment will choose, with their treating physicians,
what additional treatment should be given: more nab-Paclitaxel plus gemcitabine,
Chemoradiation therapy, or surgery to treat the locally advanced pancreatic cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society